Hallmark #7 of 12
Zombie cells that poison their neighbors
Senescent cells refuse to die and refuse to do their jobs. They secrete a toxic inflammatory cocktail called the SASP — and after age 60, they accumulate fast enough to drive tissue dysfunction across every organ system.
Cellular Senescence
Senescent cells are now recognized as the primary cellular source of the chronic low-grade inflammation (inflammaging) that drives cardiovascular disease, metabolic syndrome, neurodegeneration, and loss of physical function. The transformative finding from ITP lifespan studies is that clearing senescent cells — even starting in midlife — extends healthspan by 20–30% in mice. hs-CRP tracks SASP burden imperfectly but is the most accessible clinical proxy; p16INK4a expression in blood (available via some longevity testing panels) is a more specific readout. Fisetin and D+Q (dasatinib + quercetin) are the most evidence-backed senolytics, with Mayo Clinic RCT data now available for fisetin.
3 compound interventions · 3 trackable biomarkers
Top interventions
- BFisetin (senolytic)
- BNMN (senescence prevention)
- BResveratrol (SASP modulation)
- AExercise
- BDasatinib + Quercetin protocol
The Mechanism
The zombie cell crisis — and why the SASP is the real problem
Cellular senescence is a tumor suppression mechanism gone wrong at scale. When a cell sustains irreparable DNA damage, excessive oxidative stress, or oncogene activation, p53 and p16INK4a trigger permanent cell cycle arrest — the cell stops dividing, preventing it from passing on mutations.
In youth, immune surveillance (NK cells, macrophages) efficiently clear senescent cells within days. After age 40, immune clearance declines — and senescent cells accumulate exponentially. By age 70, senescent cells constitute 8–10% of cells in some tissues, up from under 1% at 30.
The Senescence-Associated Secretory Phenotype (SASP) is what makes senescent cells dangerous neighbors. They secrete IL-6, IL-1β, TNF-α, MMP-3, MMP-9, and dozens of other pro-inflammatory factors — converting surrounding healthy cells to senescence in a paracrine cascade known as the “bystander effect.”
SASP drives: tissue fibrosis (via TGF-β), cancer microenvironment formation (via MMP-mediated ECM breakdown), adipose inflammation (via PAI-1), and neuroinflammation (via astrocyte senescence and microglial priming). Virtually every age-related disease has senescent cell accumulation as a contributing driver.
Two Therapeutic Strategies
Senolytics
Kill senescent cells by blocking their survival pathways (BCL-2, PI3K/AKT). Goal: reduce total burden. Examples: Fisetin, D+Q, ABT-263.
Senomorphics
Suppress SASP secretion without killing senescent cells. Goal: reduce inflammatory output. Examples: Rapamycin (mTOR), Navitoclax (BCL-2), Metformin (NF-κB).
Monitoring
Biomarkers that track senescent burden
Evidence-Graded Interventions
Senolytics & senomorphics with clinical evidence
Fisetin (senolytic)
Tier BMayo Clinic trials underway. Flavonoid selectively clears senescent cells in mouse models.
NMN (senescence prevention)
Tier BNAD+ restoration delays senescence entry in cell culture via sirtuin-mediated genome stability.
Resveratrol (SASP modulation)
Tier BReduces NF-κB-driven SASP secretion in preclinical senescence models.
Exercise
Tier AClears senescent cells via immune surveillance and reduces SASP in adipose tissue.
Dasatinib + Quercetin protocol
Tier BPhysician-supervised senolytic combo. Human pilot data in IPF and diabetic kidney disease.
Fisetin (senolytic flavonoid)
Tier BMayo Clinic pilot RCT showed pulse-dose fisetin (20mg/kg × 2 days/month) significantly reduced p16INK4A and p21 senescence markers and improved physical function in older adults (PMID 30279143). Multiple Phase 2 trials active.
Build a senolytic protocol.
The Stack Architect shows which compounds target cellular senescence, their evidence tiers, and interactions with everything else in your stack.